Arlene Naranjo

Medicine · Health Sciences

45h-index7.0kcitations253works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(221), Cancer, Hypoxia, and Metabolism(70), Cancer therapeutics and mechanisms(51), Lung Cancer Research Studies(27), Adrenal and Paraganglionic Tumors(22)

Publications253 total

Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
2026Open Access
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
2026Open Access
Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
2026Open Access
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
2026Open Access
Adaptive Clinical Neuroblastoma Risk Groups—Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project
JCO Global Oncology·2025Open Access
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
2025Open Access
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
2025Open Access
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
2025Open Access
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Clinical Cancer Research·2025· 1 cited
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group
The Lancet Child & Adolescent Health·2025· 3 cited
International neuroblastoma risk group consortium: a model of networking for rare cancers
JNCI Journal of the National Cancer Institute·2025· 2 citedOpen Access
Long‐Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology Group
Pediatric Blood & Cancer·2025· 4 citedOpen Access
A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.
Journal of Clinical Oncology·2025· 4 cited
Factors associated with survival following relapse of high-risk neuroblastoma: A study from the International Neuroblastoma Risk Group (INRG) Data Commons.
Journal of Clinical Oncology·2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
Journal of Clinical Oncology·2025· 9 citedOpen Access
Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma
JAMA Network Open·2025· 1 citedOpen Access
The Late Effects after High-Risk Neuroblastoma (LEAHRN) Study - A Report from the Children's Oncology Group
SSRN Electronic Journal·2025Open Access
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology
npj Precision Oncology·2024· 11 citedOpen Access
Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531
Pediatric Blood & Cancer·2024· 1 citedOpen Access
Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group
EJC Paediatric Oncology·2024· 2 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Wendy B. London(33), Julie R. Park(27), John M. Maris(23), Susan L. Cohn(23), Michael D. Hogarty(19), Katherine K. Matthay(14), Rochelle Bagatell(12), Barry L. Shulkin(10), Marguerite T. Parisi(10), Julie M. Gastier‐Foster(9), Hiroyuki Shimada(9), Susan G. Kreissman(9), Sheena C. Tenney(8), Geetika Khanna(8), Meredith S. Irwin(7), Paul M. Sondel(7), Collin Van Ryn(6), Alice L. Yu(6), Mitchell B. Diccianni(6), Patrick McGrady(6)